INDV Indivior Pharmaceuticals, Inc.
P/E
12.18
Forward P/E
9.37
Price/Sales
3.057
Beta
1.177
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Indivior third quarter 2026 revenue of $356M beat estimates behind 22% Sublocade growth
Indivior reported third quarter 2026 results that exceeded consensus expectations on both revenue and earnings, driven by record performance of its long-acting...
Indivior PLC Q3 2026 Earnings Preview: What Analysts Expect on October 29, 2026
Indivior is expected to report Q3 2026 revenue of $326.7 million and earnings per share of $0.93, with the stock trading at $34.56 against a $45.17 average...